- Home
- IBG vs WINT Comparison
IBG vs WINT Comparison
Compare IBG & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- WINT
- Stock Information
- Founded
- IBG 2018
- WINT 1992
- Country
- IBG Australia
- WINT United States
- Employees
- IBG N/A
- WINT N/A
- Industry
- IBG Beverages (Production/Distribution)
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBG Consumer Staples
- WINT Health Care
- Exchange
- IBG Nasdaq
- WINT Nasdaq
- Market Cap
- IBG 4.1M
- WINT 3.6M
- IPO Year
- IBG 2024
- WINT 1995
- Fundamental
- Price
- IBG $0.54
- WINT $0.57
- Analyst Decision
- IBG Strong Buy
- WINT Hold
- Analyst Count
- IBG 1
- WINT 1
- Target Price
- IBG N/A
- WINT $350.00
- AVG Volume (30 Days)
- IBG 130.1K
- WINT 264.4K
- Earning Date
- IBG 06-17-2025
- WINT 05-16-2025
- Dividend Yield
- IBG N/A
- WINT N/A
- EPS Growth
- IBG N/A
- WINT N/A
- EPS
- IBG N/A
- WINT N/A
- Revenue
- IBG $2,931,243.00
- WINT N/A
- Revenue This Year
- IBG N/A
- WINT N/A
- Revenue Next Year
- IBG N/A
- WINT N/A
- P/E Ratio
- IBG N/A
- WINT N/A
- Revenue Growth
- IBG N/A
- WINT N/A
- 52 Week Low
- IBG $0.44
- WINT $0.55
- 52 Week High
- IBG $3.35
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- WINT 26.04
- Support Level
- IBG N/A
- WINT $0.67
- Resistance Level
- IBG N/A
- WINT $0.81
- Average True Range (ATR)
- IBG 0.00
- WINT 0.06
- MACD
- IBG 0.00
- WINT 0.01
- Stochastic Oscillator
- IBG 0.00
- WINT 5.24
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.